Cerebrospinal fluid glucose-to-lactate ratio (CGLR) as a diagnostic biomarker for postoperative intracranial infections in patients with acute brain injury: a prospective diagnostic accuracy study - Top-Institutions - MDSpire

Cerebrospinal fluid glucose-to-lactate ratio (CGLR) as a diagnostic biomarker for postoperative intracranial infections in patients with acute brain injury: a prospective diagnostic accuracy study

  • By

  • Weidong Wang

  • Huajun Wang

  • Chengjie Zhou

  • Ye Fu

  • June 10, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Affiliated People’s Hospital of Ningbo University
    Affiliated People’s Hospital of Ningbo University

    Ningbo, Zhejiang

    Key Differentiators

    • Neurology

  • #2

    Uppsala University Hospital
    Uppsala University Hospital

    Uppsala, Uppsala

    Key Differentiators

    • Neurology

  • #3

    Karolinska University Hospital Huddinge
    Karolinska University Hospital Huddinge

    Huddinge, Stockholm

    Key Differentiators

    • Neurology

  • #4

    University of Health Sciences
    University of Health Sciences

    Istanbul, Istanbul

    Key Differentiators

    • Neurology

  • #5

    Bağcılar Training and Research Hospital
    Bağcılar Training and Research Hospital

    Istanbul, Istanbul

    Key Differentiators

    • Neurology

Original Source(s)

Cerebrospinal fluid glucose-to-lactate ratio (CGLR) as a diagnostic biomarker for postoperative intracranial infections in patients with acute brain injury: a prospective diagnostic accuracy study

  • by Weidong Wang, Huajun Wang, Chengjie Zhou, Ye Fu

  • June 10, 2026

Related Content

Acupuncture for Neuroinfections?

A recent Perspective offered a speculative mechanistic argument for acupuncture’s potential role as an adjunctive strategy in neuroinfectious diseases.

Napkin-ring sign plaques are associated with clinical outcome in patients with acute ischemic stroke after endovascular therapy

Successful rescue therapy with eculizumab for probable tislelizumab-related MMM overlap syndrome with dual positivity for anti-acetylcholine receptor and anti-titin antibodies: a case report and literature review